O'Brien R M, Byron K A, Varigos G A, Thomas W R
University of Melbourne Department of Medicine, Western Hospital, Footscray, Australia.
Clin Exp Allergy. 1997 Jan;27(1):46-51.
Allergen-specific immunotherapy (IT) can be an important adjunctive therapy in the treatment of allergic disorders. Although it has now been used for over 80 yr, the precise mechanism of action remains unclear. Recently a number of studies have shown that cytokine production may be modified by IT, but different protocols have been used and different results obtained.
The aims of the present study were: (1) to document the allergen-specific expression of interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) by peripheral blood cells in both untreated house dust mite (HDM) allergic patients (non-IT) and following at least 10 months of HDM-specific IT (post-IT); and (2) to determine whether alterations in these critical regulatory cytokines correlated with the clinical outcome of IT.
IT was undertaken with nine fortnightly subcutaneous injections of increasing amounts of a Dermatophagoides pteronyssinus (Dpt) extract, reaching a final dose of 10,000 PNU. This was followed by 6- to 8-monthly maintenance injections of 5000 PNU. For cytokine measurement, mononuclear cells were separated from peripheral blood and stimulated with the major Dpt allergen, Der p 2, for 18 h, after which mRNA was isolated and IL-4 and IFN-gamma cDNA were amplified by polymerase chain reaction (PCR). The presence of the particular cytokine was determined by visualization following electrophoresis on an agarose gel. The study was observational in nature being open and without a placebo group.
Fifteen Dpt-sensitive patients who had not received HDM IT (non-IT), and 16 who had, were studied. In the non-IT group, 80% expressed IL-4 and 75% expressed IFN-gamma. In those post-IT, only 12.5% expressed IL-4 and 19% IFN-gamma. The two patients still expressing IL-4 post-IT had had very little clinical response. Six patients were studied both pre- and post-IT. Prior to IT, three were positive for both cytokines, two positive for IL-4 alone and one for IFN-gamma. Post-IT, all six were negative for IL-4 and five were negative for IFN-gamma.
Allergen-specific IT results in a reduction in expression of the critical cytokines IL-4 and IFN-gamma in circulating lymphocytes. It is possible that this is a contributary mechanism in the beneficial effect of IT.
变应原特异性免疫疗法(IT)在过敏性疾病的治疗中可以是一种重要的辅助疗法。尽管其现已应用超过80年,但其确切作用机制仍不清楚。最近一些研究表明,IT可能会改变细胞因子的产生,但使用了不同的方案并获得了不同的结果。
本研究的目的是:(1)记录未治疗的屋尘螨(HDM)过敏患者(非IT组)以及至少接受10个月HDM特异性IT治疗后(IT后组)外周血细胞白细胞介素-4(IL-4)和干扰素-γ(IFN-γ)的变应原特异性表达;(2)确定这些关键调节性细胞因子的改变是否与IT的临床结果相关。
采用每两周皮下注射一次的方法进行IT治疗,逐渐增加尘螨提取物的剂量,最终剂量达到10,000 PNU。之后每6至8个月注射5000 PNU进行维持治疗。为了检测细胞因子,从外周血中分离单核细胞,并用主要的尘螨变应原Der p 2刺激18小时,然后分离mRNA,通过聚合酶链反应(PCR)扩增IL-4和IFN-γ cDNA。通过琼脂糖凝胶电泳后的可视化来确定特定细胞因子的存在。本研究本质上是开放性观察性研究,没有安慰剂组。
研究了15名未接受HDM IT治疗的尘螨敏感患者(非IT组)和16名接受过治疗的患者。在非IT组中,80%表达IL-4,75%表达IFN-γ。在IT后组中,只有12.5%表达IL-4,19%表达IFN-γ。两名IT后仍表达IL-4的患者临床反应非常小。对6名患者在IT前后均进行了研究。IT前,3名患者两种细胞因子均为阳性,2名仅IL-4阳性,1名IFN-γ阳性。IT后,所有6名患者IL-4均为阴性,5名患者IFN-γ为阴性。
变应原特异性IT导致循环淋巴细胞中关键细胞因子IL-4和IFN-γ的表达降低。这可能是IT产生有益效果的一个促成机制。